Novel Insights in the Modern Medical Management of Acromegaly
Nieuwe inzichten in de moderne medische behandeling van acromegalie
The main aim of this thesis was to assess the efficacy and safety of pasireotide LAR treatment in patients with acromegaly controlled with first-generation somatostatin analogues and pegvisomant.
In chapters 3 and 4 we report the results of the PAsireotide LAR and PEgvisomant study (PAPE) study.
Chapter 5 we assessed whether somatostatin receptor subtype 2 and 5 protein expression correlates and predicts response to pasireotide LAR treatment in the PAPE study.
In chapter 6 we assessed plasma acylated and unacylated ghrelin levels in acromegaly patients using first-generation somatostatin analogues and pegvisomant combination treatment.
Finally in chapter 7 we report the results of a pilot study evaluating whether pegvisomant is expressed in the liver and wheter kupffer cells are involved in the clearance of pegvisomant in two patients with acromegaly.
|Keywords||acromegaly, pituitary, pasireotide, somatostatin, pegvisomant, growth hormone, clinical trial|
|Promotor||A.J. van der Lelij (Aart Jan) , S.J.C.M.M. Neggers (Bas)|
|Publisher||Erasmus University Rotterdam|
|Note||For copyright reasons there is a partial embargo for this dissertation|
Muhammad, A. (2019, September 10). Novel Insights in the Modern Medical Management of Acromegaly. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/118967
|Cover-Muhammad.PNG Cover Image , 120kb|
|118967_Chapter_1-General_introduction_and_aims_of_the_the.pdf Final Version , 901kb|
|118967_Chapter_2-What_is_the_efficacy_of_switching_to_wee.pdf Final Version , 327kb|
|118967_Chapter_4-Efficacy_and_safety_of_switching_to_pasi.pdf Final Version , 548kb|
|118967_Chapter_5-Pasireotide_responsiveness_in_acromegaly.pdf Final Version , 3mb|
|118967_Chapter_6-The_acylated_unacylated_ghrelin_ratio_is.pdf Final Version , 388kb|
|118967_Chapter_8-General_discussion_and_future_perspectiv.pdf Final Version , 707kb|